Scipher will use the proceeds to further commercialize PrismRA, a molecular test intended to guide treatment decisions for patients with rheumatoid arthritis.
CellMax also completed a Series C financing round to speed up development of itsFirstSight liquid biopsy test to detect colorectal cancer and precancer polyps.
The startup will use the funds to support R&D and to launch its Qsant urine test to help determine if a patient's body is rejecting a kidney transplant.